Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27363735 | 0.84 | KCNH2 (0.48) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL9321232 | 0.80 | BCL2 (0.42) | BCL2BCL2L1ALDH1A1L3MBTL1BRD4 | |
| SCHEMBL5749742 | 0.79 | HRH4 (0.49) | BCL2BCL2L1ALDH1A1BRD4IDH1 | |
| SCHEMBL9323212 | 0.75 | POLB (0.49) | BCL2BCL2L1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4447913 | 0.75 | HRH4 (0.43) | SMN1; SMN2TDP1L3MBTL1POLBMEN1 | |
| SCHEMBL9321241 | 0.73 | KCNH3 (0.49) | SMN1; SMN2BRD4MEN1KMT2A | |
| SCHEMBL9741308 | 0.72 | SMN1; SMN2 (0.44) | BCL2BCL2L1ALDH1A1SMN1; SMN2IDH1 | |
| SCHEMBL503238 | 0.71 | NOS3 (0.36) | — | |
| SCHEMBL229621 | 0.71 | BCL2 (0.48) | BCL2BCL2L1ALDH1A1L3MBTL1IDH1 | |
| SCHEMBL12036993 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157174-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2017-06-08 | — | — | US | disclosed |
| EP-2349245-B1 | TREATMENT OF LATENT HIV-1 INFECTIONS USING AURANOFIN OR ARSENIC TRIOXIDE | Istituto Superiore di Sanità (IT) | 2016-08-03 | — | — | EP | disclosed |
| US-20150024065-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2015-01-22 | — | — | US | disclosed |
| US-8785493-B2 | Treatment of retroviral reservoirs exploiting oxidative stress | ISTITUTO SUPERIORE DI SANITA (IT) | 2014-07-22 | — | — | US | disclosed |
| US-20110305774-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITA (IT) | 2011-12-15 | — | — | US | disclosed |
| EP-2349245-A2 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | Istituto Superiore di Sanità (IT) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010049182-A2 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | ISTITUTO SUPERIORE DI SANITÁ (IT) | 2010-05-06 | — | — | WO | disclosed |
| US-7589137-B2 | Resin composition and molded product obtained therefrom | SONY CORPORATION (JP) | 2009-09-15 | — | — | US | disclosed |
| US-7589137-B2 | Resin composition and molded product obtained therefrom | SONY CORPORATION (JP) | 2009-09-15 | — | — | US | disclosed |
| US-5332745-A | Fungicides | SHELL RESEARCH LIMITED (GB) | 1994-07-26 | — | — | US | disclosed |
| EP-0469685-A1 | Tetrahydropyrimidine derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305774-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | TXNRD1, TXNRD3, TXNRD2 | BCL2 402/4885BCL2L1 591/4885ALDH1A1 1318/4885 |
| US-20170157174-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | TXNRD1, TXNRD3, TXNRD2 | BCL2 402/4885BCL2L1 591/4885ALDH1A1 1318/4885 |
| US-20150024065-A1 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS | TXNRD1, TXNRD3, TXNRD2 | BCL2 402/4885BCL2L1 591/4885ALDH1A1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.